Nektar Moves Up Planned Hair-Loss Trial Start To December As Research Spending Rises
The drug developer held $952.9 million in cash and investments as it advanced rezpegaldesleukin into late-stage testing.
Nektar Therapeutics, which is testing rezpegaldesleukin for eczema and hair loss, plans to start its late-stage alopecia areata trial in December, ahead of its previous timetable. The company outlined the earlier trial start in Thursday’s earnings release accompanying its 8-K, alongside $952.9 million in cash and marketable investments.
December Start, 2028 Results
Howard Robin, Nektar’s president and chief executive officer, said the global hair-loss trial was on track for December, “earlier than previously planned,” in the earnings release.
Nektar expects initial results in summer 2028 and targets its first FDA approval application in 2029. Rezpegaldesleukin is an experimental injection intended to change immune responses; Nektar also develops other experimental medicines and licenses drug technologies to pharmaceutical and biotechnology companies.
The eczema program already has its late-stage trials underway. Nektar began the first trials in July and announced the final trial in October, enrolling patients previously treated with biologic medicines or JAK inhibitors. The company aims to support a broad approved use for the drug.
Results from the earlier eczema study’s 16-week treatment period appeared in The Lancet in August. The study met its main and key secondary goals, including measures of eczema severity and itching.
Hair Regrowth After Treatment Stopped
Nektar’s October update provided follow-up evidence from patients with severe-to-very-severe alopecia areata. Among eight patients who reached the specified scalp-hair response threshold after 52 weeks of treatment, six, or 75%, retained that response four months after stopping treatment; five, or 63%, retained it at six months.
Hair regrowth continued during the six-month period without treatment. The proportion reaching the study’s stricter scalp-hair threshold rose to 19% from 7% at the end of treatment. Nektar said those findings support evaluating less frequent dosing for patients who achieve the response threshold.
More Cash, Higher Trial Costs
Cash and marketable investments stood at $952.9 million at September’s end, up from $245.8 million at the end of 2025.
Third-quarter research spending rose to $44.1 million from $27.3 million a year earlier. Nektar attributed the increase mainly to late-stage eczema and alopecia trials and rezpegaldesleukin manufacturing work. Research spending for the first nine months reached $118.9 million, versus $87.6 million a year earlier.
Administrative expenses increased to $24.6 million from $16.1 million in the quarter, primarily because of higher legal expenses, Nektar said. For the first nine months, administrative spending fell to $50.8 million from $57.5 million, which the company attributed mainly to lower legal expenses over that period.
Quarterly revenue declined to $9.4 million from $11.8 million and consisted entirely of non-cash royalties associated with future royalty rights Nektar previously sold. Nine-month revenue fell to $30.4 million from $33.4 million.
The quarterly net loss widened to $55.7 million from $35.5 million, while loss per share narrowed to $1.63 from $1.87. The weighted-average share count used in that calculation was 34,178,219, versus 18,946,559 a year earlier. For the first nine months, the net loss rose to $141.2 million from $128.0 million, with per-share losses of $4.60 versus $8.14.
December is the planned start for the hair-loss trial; Nektar’s next stated initial-results milestone is summer 2028.
Sources
- 8-K Filing — NEKTAR THERAPEUTICS (NKTR) — SEC EDGAR
- Exhibit ea031199801ex99-1.htm — NEKTAR THERAPEUTICS 8-K exhibit — SEC EDGAR
- How New Eczema Drug Trials Will Impact Nektar Therapeutics (NKTR) Investors — Yahoo Finance
- Nektar Therapeutics Announces Third Quarter 2026 Financial Results — prnewswire.com
- Nektar Therapeutics to Participate in Two Investor Conferences in November — prnewswire.com
- 8-K filed 2026-10-01 — NEKTAR THERAPEUTICS (earlier disclosure) — SEC EDGAR